Palvella Therapeutics, Inc. Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent
Palvella Therapeutics, Inc. (PVLA) reported Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent of $100.00 thousand for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent · last filed 2020-05-11
- Palvella Therapeutics, Inc. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for the quarter ending 2019-09-30 was $100.00K.
- Palvella Therapeutics, Inc. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for the quarter ending 2019-06-30 was $100.00K.
- Palvella Therapeutics, Inc. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for the quarter ending 2019-03-31 was $100.00K.
| Period end | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent 9 month |
|---|---|---|---|
| 2019-09-30 | $100.00K 10-Q · filed 2019-11-12 | $200.00K derived: sum of 2 quarters · filed 2019-11-12 | $100.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $100.00K 10-Q · filed 2019-08-09 | $100.00K 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $100.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |